You are here

IMCgp100 Trials

*** UPDATE: DEC 2017 - IMCgp100 gets FASTRACK in UK - jump out to the news article website HERE ***

Though only in trial format this treatment is showing some promise. It is possible to access the trial in the UK. Unfortunately it only works for a subset of OM patients at the moment. Like all trials there is criteria the patient must meet . One of those is he/she has to  be of HLA-2 status so this will need to be tested before applying to the trial.  Around half of uveal melanoma patients are HLA-2 positive. This is a simple blood test and can be done here in Ireland.

 

Below is an extart from the 13/11/17 press release. You can read the full article here

 

Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate

~ Data shows a 73% one-year survival rate for metastatic uveal melanoma patients treated in two Phase I studies of IMCgp100 ~

(Oxford, UK and Conshohocken, US, 13 November 2017) Immunocore Limited, the world's leading TCR company developing biological drugs to treat cancer and infectious diseases, today announces durable tumour responses and strong overall survival data from two Phase I clinical trials of its wholly owned, lead programme, IMCgp100, in metastatic uveal melanoma.

The data, which show a near doubling in the average rate of overall survival compared with studies of other agents, was presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting on Saturday 11th November 2017, at the Gaylord National Resort & Convention Center in National Harbor, Maryland, USA.

Immunocore's intra-patient dose escalation Phase I IMCgp100 study in metastatic uveal melanoma patients demonstrates a one-year overall survival (OS) rate of 73% (95% confidence interval [46, 88]) and a one-year progression-free-survival (PFS) rate of 62% based on the irRC criteria as of the data cut-off in October 2017. Median OS has not been reached with median follow-up of 12.8 months in this cohort.  The overall survival data from this study compare very favourably to studies with other agents, which show one-year OS rates of approximately 25-45%*.

Pharmacodynamic analysis demonstrated evidence of T cell infiltration and immune activation in tumours after IMCgp100 administration, with persistence of T cell infiltration in the setting of resistance, underpinning confidence in the efficacy observed with the T cell redirection technology of IMCgp100.

Add new comment

Filtered HTML

  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Theme by Danetsoft and Danang Probo Sayekti inspired by Maksimer